Monitor the upcoming FDA alignment on tagmokitug's expedited development path in second-line esophageal cancer and the trajectory of LOQTORZI revenue growth toward the $25M-$30M quarterly core cash burn breakeven target.
Drugs in focus
CHRS drug pipeline →LOQTORZI
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. since October 2023.
- Next catalyst
- None dated
What to watchLOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $0.6409entry
- T+1 · 6d ago −9.11%α −10.43% · $0.5825
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per share, beating the consensus estimate of $(0.21). The company announced a strategic prioritization of tagmokitug in esophageal cancer, a ~30% headcount reduction, and guided to lower quarterly cash burn of $6M-$7M. Cash and equivalents fell to $83.6M from $172.1M at year-end 2025.
Key Financial Metrics
Key Facts
- Q3 2026 net revenue $14.3M vs $11.6M YoY (+23%)
- Non-GAAP EPS $(0.20) vs consensus $(0.21) (beat)
- LOQTORZI net revenue $14.0M, up 25% YoY
- Headcount reduction of ~30% to lower core cash burn by $6M-$7M quarterly
- Cash and marketable securities $83.6M as of Sep 30, 2026, down from $172.1M at Dec 31, 2025
- Net loss from continuing operations $(38.9M) vs $(44.5M) YoY
- R&D expenses $22.6M, down from $27.3M YoY
- SG&A expenses $21.2M, down from $24.9M YoY
- Company focusing tagmokitug development on esophageal cancer, deprioritizing other indications
Financial Impact
Revenue $14.3M, non-GAAP net loss $(31.2M), cash burn reduction guided to $6M-$7M quarterly
Risk Factors
- Cash runway limited to ~2-3 quarters at current burn rate without additional financing
- Strategic pivot to esophageal cancer carries clinical and regulatory execution risk
- LOQTORZI revenue growth may not reach self-sufficiency targets
- Headcount reduction may impact operational capacity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398986 |
Track record
15 reports on CHRS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers